|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficient engagement with the envelope glycoprotein membrane-proximal external region (MPER) results in robust blocking of viral infection by a class of broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV).
|
31787208 |
2020 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Attachment of envelope glycoprotein gp120 to the host cell receptor CD4 is the first step during the human immunodeficiency virus-1 (HIV-1) entry into the host cells that makes it a promising target for drug design.
|
31792886 |
2020 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to these anti-cancer properties, man-specific seaweed lectins have been widely used as potent human immunodeficiency virus (HIV-1)-inactivating proteins, due to their capacity to specifically interact with the envelope glycoprotein gp120 and prevent the virion infectivity of HIV-1 towards the host CD4+ T-lymphocyte cells in vitro.
|
31357490 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SOS change exerted more subtle, context-dependent effects on Env conformation and function.<b>IMPORTANCE</b> The human immunodeficiency virus type 1 (HIV-1) envelope proteins (Envs) bind receptors on the host cell and change shape to allow the virus to enter the cell.
|
30944182 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Passively administered broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have been shown to protect non-human primates (NHPs) against chimeric simian-human immunodeficiency virus (SHIV) infection.
|
31513771 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Binding to the receptor CD4 triggers entry-related conformational changes in the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer, (gp120/gp41)<sub>3</sub> Soluble versions of HIV-1 Env trimers (sgp140 SOSIP.664) stabilized by a gp120-gp41 disulfide bond and a change (I559P) in gp41 have been structurally characterized.
|
30429345 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neutralizing antibodies against human immunodeficiency virus subtype 1 (HIV-1) bind to its envelope glycoprotein (Env).
|
31607367 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the entry process, the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer undergoes a sequence of conformational changes triggered by both CD4 and coreceptor engagement.
|
30650070 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
An envelope glycoprotein, gp41, is crucial for the entry of human immunodeficiency virus (HIV) into the host cell.
|
31345037 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The N-terminal fusion peptide (FP) of the human immunodeficiency virus (HIV)-1 envelope glycoprotein (Env) gp41 subunit plays a critical role in cell entry.
|
30770829 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
PF-68742 is a small molecule that inhibits the infection of a subset of HIV-1 strains by interfering with an Env function other than receptor binding.
|
31391272 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human immunodeficiency virus (HIV-1) entry is initiated by the binding between the viral envelope glycoprotein gp120 and the host receptor CD4, and followed by reduction of structural disulfides of gp120 and CD4.
|
30948772 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The envelope glycoprotein gp120 is exposed on the surface of the HIV envelope, essential for virus entry into cells by the attachment to specific cell surface receptors.
|
30873925 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the molecular docking of virus-entry molecule (gp120 envelope glycoprotein) revealed the key interacting residues of the protein (cellular receptor, CD4) and the site-moiety preferences of colchicine derivatives as HIV entry inhibitors for binding to HIV structure.
|
30251609 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cellular tropism of human immunodeficiency virus (HIV-1) is closely linked to interactions between the viral envelope glycoprotein (Env) with CD4 and chemokine receptor family members, CCR5 and CXCR4.
|
29173176 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human immunodeficiency virus (HIV) envelope glycoprotein (glycoprotein 120, gp120) can induce chronic neuropathic pain by directly stimulating primary sensory afferent neurons.
|
28827078 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously reported that the CBD1 peptide (SLEQIWNNMTWMQWDK), corresponding to the consensus caveolin-1 binding domain in human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp41, elicits peptide-specific antibodies.
|
29976675 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) encodes specific trafficking signals within its long cytoplasmic tail (CT) that regulate incorporation into HIV-1 particles.
|
29212940 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The gp41 transmembrane domain of the envelope glycoprotein of the human immunodeficiency virus (HIV) modulates the conformation of the viral envelope spike.
|
30199809 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Small-molecule CD4-mimetic compounds (CD4mc) inhibit human immunodeficiency virus (HIV-1) entry by blocking binding to the CD4 receptor and by premature triggering of the viral envelope glycoprotein (Env) spike.
|
29617845 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed the effect of the HIV envelope glycoprotein gp120 on GBM cell proliferation.
|
30200472 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
VRC01 broadly neutralizing antibodies (bnAbs) target the CD4-binding site (CD4<sub>BS</sub>) of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein (Env).
|
30403372 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The V3 loop of the human immunodeficiency virus type 1 (HIV-1) gp120 exterior envelope glycoprotein (Env) becomes exposed after CD4 binding and contacts the coreceptor to mediate viral entry.
|
29936340 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
|
29618643 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results presented here suggest that the SOSIP changes stabilize Env in a conformation that differs from State 1 but also from the downstream Env conformations stabilized by L193R or I423A.<b>IMPORTANCE</b> The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer is triggered by receptor binding to mediate the entry of the virus into cells.
|
30021898 |
2018 |